Last updated
TB-500 and GHK-Cu both get filed under “repair,” but they do different jobs in different tissue. TB-500 mobilizes cells to a wound by regulating actin; GHK-Cu delivers copper and reshapes the extracellular matrix, mostly in skin. Together with BPC-157, they form a trio of repair peptides that are frequently grouped and rarely distinguished.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | TB-500 | GHK-Cu |
|---|---|---|
| Structure | Synthetic fragment of thymosin β4 (LKKTETQ motif) | Copper-bound tripeptide (Gly-His-Lys) |
| Primary mechanism | G-actin sequestration → directed cell migration | Copper delivery + ECM-remodeling gene modulation |
| Target tissue | Soft tissue, cardiac, dermal (systemic) | Skin, extracellular matrix, hair follicle |
| Best-studied for | Cell migration, wound and cardiac repair | Collagen / elastin synthesis, skin aging, wound healing |
| Typical route (research) | Injected (systemic) | Topical / local (also injectable) |
| Evidence base | Preclinical; much derived from thymosin β4 itself | Extensive dermatologic / cosmetic literature, incl. human topical data |
| Status | Research compound — WADA-prohibited; not FDA-approved | Cosmetic ingredient (Copper Tripeptide-1) / research |
| Molecular weight | ~4900 Da (peptide fragment) | 401.9 Da |
TB-500 corresponds to the actin-binding region of thymosin β4, a protein involved in cell migration and tissue repair. By sequestering monomeric G-actin it influences the cytoskeletal dynamics that let cells mobilize toward an injury, with research interest in soft-tissue, cardiac, and dermal repair. Its evidence is largely preclinical — and much of it derives from thymosin β4 as a whole rather than the TB-500 fragment specifically — and it is a research compound, prohibited in sport and not FDA-approved.
GHK-Cu comes at repair from the matrix side. It is the copper complex of the tripeptide glycyl-histidyl-lysine, first isolated from human plasma in 1973, and it works by delivering copper — a cofactor for matrix-remodeling and antioxidant enzymes — while shifting the expression of extracellular-matrix genes. Its literature is concentrated in dermatology and cosmetics, including human topical data, where it is the reference copper peptide for collagen support and skin aging. So the two overlap only in the loose category of “repair”: TB-500 is a systemic, migration-driving research peptide; GHK-Cu is a mostly topical, matrix-remodeling copper peptide with a deeper cosmetic record.
Complementary, not interchangeable. TB-500 is studied for mobilizing cells into injured tissue via actin regulation, with a preclinical evidence base and a WADA prohibition; GHK-Cu is the reference copper peptide for skin and extracellular-matrix remodeling, with a broader dermatologic literature. Neither is an FDA-approved drug — GHK-Cu is a cosmetic ingredient, TB-500 a research compound. Grouping them (and BPC-157) as one “recovery” category obscures how differently they act. This page is a research and educational reference.
TB-500 is a synthetic fragment of thymosin β4 that promotes cell migration by regulating actin, studied for soft-tissue and cardiac repair. GHK-Cu is a copper-bound tripeptide that delivers copper and remodels the extracellular matrix, mainly in skin. Different structures, mechanisms, and target tissue.
They are sometimes grouped in “recovery” contexts (often with BPC-157), but because they act on different mechanisms and tissue there is no controlled human data on the combination. This page is a research reference, not a protocol.
GHK-Cu has the deeper literature, especially in dermatology and cosmetics, including human topical studies. TB-500’s evidence is preclinical, and much of it derives from thymosin β4 rather than the fragment itself.
No. TB-500 is a research compound and is prohibited in sport; GHK-Cu is used as a cosmetic ingredient (Copper Tripeptide-1), not an approved drug. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between TB-500 and GHK-Cu — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.